sell on the news, page-25

It's the next deal or two and the rate at which they arrive that will either kick off a sustained rise, or not IMO.

For what it's worth Affymetrix said this re their ebioscience takeover play:

"Affymetrix says the acquisition will complement its traditional businesses of genomics and cytogenetics, enhance its molecular diagnostics business, and expand its product portfolio to include multicolor flow cytometry reagents and a range of reagents for analyzing cytokines, growth factors, and other soluble proteins. The takeover will in addition boost new product and growth opportunities for its Panomics subsidiary’s RNA and protein analysis business."

And eBioscience said this about the mix & go deal :

"Don Tartre, President and CEO of eBioscience, said: “We are pleased to work in partnership with the Anteo Diagnostics team to exploit an innovative technology to leverage our FlowCytomixTMbead-based immunoassay product line to even higher performance including greater sensitivity. This is yet another way by which eBioscience looks to deliver to its customers innovative products that demonstrate superior performance.”

So to me that's saying you have a leader in its field being taken over for its technical speciality and this specialist has now chosen to use m&g.

This deal re-validates to me that the tech is good, the patents restrict the use of it unless you pay and I take from this that there will be more companies willing to pay!